Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2023-10-03 Legal Proceedings Report
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA RECEIVES APPROVAL FROM THE MONTPELLIER COMMERCIAL COURT TO OPEN A SAFEGUARD PROCEDURE
Legal Proceedings Report Classification · 99% confidence The document is titled 'PRESS RELEASE' and announces a specific corporate event: 'MEDESIS PHARMA RECEIVES APPROVAL FROM THE MONTPELLIER COMMERCIAL COURT TO OPEN A SAFEGUARD PROCEDURE'. This is a material, non-periodic announcement regarding a significant legal/financial restructuring event. It is not a full annual report (10-K), an earnings release (ER), or a standard quarterly report (IR). Since it is a specific, material announcement that doesn't fit the highly specific categories like DIRS, DIV, or MANG, it falls best under the general regulatory announcement category, 'Regulatory Filings' (RNS), as it is a press release detailing a legal/financial status update. Given the document length (2460 chars) and content (announcement of a court procedure), it is a direct announcement, not a report publication announcement (RPA).
2023-10-03 English
MEDESIS PHARMA OBTIENT UN ACCORD POUR L’OUVERTURE D’UNE PROCÉDURE DE SAUVEGARDE AUPRÈS DU TRIBUNAL DE COMMERCE DE MONTPELLIER
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 3, 2023, announcing that MEDESIS PHARMA has obtained the opening of a 'procédure de sauvegarde' (safeguard procedure) from the Commercial Court of Montpellier. This procedure is a legal/financial restructuring mechanism designed to help companies resolve difficulties without being in a state of insolvency. This type of announcement, detailing legal proceedings, restructuring efforts, and financial protection measures, fits best under the 'Legal Proceedings Report' (LTR) category, as it directly relates to significant legal/regulatory action impacting the company's operations and financial status. It is not a standard earnings release (ER), capital change (CAP), or general regulatory filing (RNS), but a specific report on a legal/restructuring event.
2023-10-03 French
MEDESIS PHARMA RECOGNIZED AS A 2023 PRIX GALIEN USA NOMINEE FOR BEST STARTUP
Regulatory Filings Classification · 100% confidence The document is a press release dated August 3, 2023, announcing that MEDESIS PHARMA has been named a 2023 Prix Galien USA Award nominee for 'Best Startup.' This is an announcement regarding an award nomination and recognition, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). It is a general corporate announcement concerning recognition and industry news. Since there is no specific category for 'Award Nomination Announcement,' and it is a general corporate update that doesn't fit MANG (Board/Management change), DIV (Dividend), or CAP (Financing), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for non-standard corporate news releases.
2023-08-02 English
MEDESIS PHARMA NOMINÉE POUR LE PRIX GALIEN USA 2023 DE LA MEILLEURE STARTUP
Regulatory Filings Classification · 100% confidence The document is a press release dated August 3, 2023, announcing that MEDESIS PHARMA has been nominated for the Galien USA Award 2023 in the 'Best Startup' category. It details the award, the nominating bodies (Galien Foundation and Business France), and provides background information on the company and the award. This type of announcement, which is a general corporate update about an award nomination and not a mandatory regulatory filing (like 10-K, ER, or IR), fits best under the general 'Regulatory Filings' or 'Miscellaneous' category, as there is no specific category for 'Award Nomination Announcement'. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate classification for a press release detailing a corporate achievement/nomination that doesn't fit the other specific financial or operational categories.
2023-08-02 French
MEDESIS PHARMA PRÉSENTE UN POSTER SCIENTIFIQUE À LA CONFÉRENCE INTERNATIONALE DE L''ASSOCIATION ALZHEIMER À AMSTERDAM
Regulatory Filings Classification · 95% confidence The document is a press release dated July 13, 2023, announcing that Medesis Pharma will present a scientific poster at the Alzheimer's Association International Conference (AAIC) in Amsterdam. It details the ongoing Phase II study for NanoLithium, recruitment status, and expected results timeline. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is an announcement related to ongoing research and clinical trials, which often falls under general corporate or investor news. Since it is a formal announcement about scientific progress and conference participation, and does not fit the specific categories like M&A (TAR), Capital (CAP), or Dividend (DIV), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Given the context of a press release announcing scientific findings being presented, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as it is a formal corporate communication that doesn't fit the other specific categories like ER or IR. The document length (4120 chars) is short, but it is the primary content, not an announcement *of* another document, so RPA is not applicable.
2023-07-13 French
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM
Investor Presentation Classification · 90% confidence The document is a press release from MEDESIS PHARMA announcing its participation in the Alzheimer's Association International Conference (AAIC) and the presentation of a scientific poster describing the design of their NanoLithium study. It details the study's progress (final recruitment stage, results expected Q1 2024) and provides background on the company's technology (Aonys®). This type of announcement, focusing on scientific updates, conference participation, and R&D progress, is characteristic of an Investor Presentation (IP) or a general press release related to investor/scientific communication. Since it is not a formal regulatory filing (like 10-K or IR), nor a transcript (CT), nor a formal earnings release (ER), and it presents detailed scientific/pipeline information intended for investors, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. Given the options, 'IP' covers detailed scientific/pipeline updates better than the general 'RNS'. However, because it is a short announcement *about* presenting data rather than the data itself, and it is a general corporate communication, 'RNS' (Regulatory Filings/General Announcement) is also a strong candidate if 'IP' is reserved strictly for slide decks. Given the content focuses heavily on the scientific study and its implications for the drug pipeline, 'IP' is chosen as the best fit for substantive investor-facing scientific communication, even if delivered via a press release format. The document length is short (3740 chars), suggesting it's an announcement rather than a full report.
2023-07-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.